Eugene Bauer - 09 Dec 2025 Form 4 Insider Report for Evommune, Inc.

Reporting relationship
Chief Medical Officer, Director
Issuer ticker
EVMN on NYSE
Reported as of
09 Dec 2025
Net transaction value
-$26,368
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
11 Dec 2025, 16:18:49 UTC
Prior SEC filing
19 Dec 2025
Next SEC filing
17 Apr 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Gregory S. Moss, Attorney-in-Fact

Key filing fact

Eugene Bauer filed Form 4 for Evommune, Inc. on 11 Dec 2025.

Key facts

  • This page summarizes Eugene Bauer's Form 4 filing for Evommune, Inc..
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 11 Dec 2025, 16:18.

Change

  • Previous filing in this sequence was filed on 19 Dec 2025.
  • Current net transaction value: -$26,368.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001678620 Primary reporting owner

Bauer Eugene

Relationship
Chief Medical Officer, Director
Address
C/O EVOMMUNE, INC., 1841 PAGE MILL ROAD, SUITE 100, PALO ALTO
Signature
/s/ Gregory S. Moss, Attorney-in-Fact
Signature date
11 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EVMN transaction

Common Stock

Tax liability

Transaction value
$26,368
Shares
-1,478
Change %
-0.54%
Price
$17.84
Shares after
270,818
Date
09 Dec 2025
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .